Patents by Inventor Michael Feldhaus

Michael Feldhaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
    Publication number: 20240109975
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: August 15, 2023
    Publication date: April 4, 2024
    Applicant: SEAGEN INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR
    Publication number: 20230399386
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 14, 2023
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, Karl Dane Wittrup
  • RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR
    Publication number: 20230348901
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
    Type: Application
    Filed: July 1, 2022
    Publication date: November 2, 2023
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • BCMA antibodies and use of same to treat cancer and immunological disorders
    Patent number: 11767365
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: September 26, 2023
    Assignee: Seagen Inc.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Antibodies against BACE1 and use thereof for neural disease immunotherapy
    Patent number: 11746160
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: September 5, 2023
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus
  • T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
    Patent number: 11471490
    Abstract: Immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 18, 2022
    Assignee: Torque Therapeutics, Inc.
    Inventors: Thomas L. Andresen, De-Kuan Chang, Douglas S. Jones, Jesse Lyons, Jonathan D. Nardozzi, Ulrik B. Nielsen, Michael Feldhaus
  • Methods of Purifying Masked Antibodies
    Publication number: 20220306727
    Abstract: The present invention relates to the field of antibody formulations. In particular, the present invention relates to specific methods of preparing masked antibodies with reduced aggregation. In some embodiments, the masked antibodies comprise anti-CD47 antibodies.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 29, 2022
    Applicant: Seagen Inc.
    Inventors: Elise Cunningham, Susan Lee, Danielle Leiske, Catherine Eakin, Kevin Beam, Lori Westendorf, Michael Feldhaus, Samuel Pearce Alcoba
  • Masked Antibody Formulations
    Publication number: 20220233709
    Abstract: Formulations comprising masked antibodies are provided. In some embodiments, there is reduced aggregation of the masked antibodies in the formulations. In various embodiments, the formulations are pharmaceutical formulations suitable for use in therapeutic treatment.
    Type: Application
    Filed: June 4, 2020
    Publication date: July 28, 2022
    Applicant: Seagen Inc.
    Inventors: Danielle Leiske, Elise Cunningham, Shan Jiang, Lori Westendorf, Michael Feldhaus, Eoin Francis James Cosgrave, Catherine Marie Eakin
  • CD47 Antibodies and Uses Thereof for Treating Cancer
    Publication number: 20220135674
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
    Publication number: 20220025062
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 27, 2022
    Applicant: SEAGEN INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • CD47 antibodies and uses thereof for treating cancer
    Patent number: 11180552
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 23, 2021
    Assignee: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • Anti-ALK antibodies and methods for use thereof
    Patent number: 11091559
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to ALK, a receptor tyrosine kinase, and modulate the expression and/or activity of ALK. Also provided are uses and methods for treating, e.g., managing, disorders, such as cancer.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: August 17, 2021
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Diego Alvarado, Jay Lillquist, Gwenda Ligon, Michael Feldhaus
  • BCMA antibodies and use of same to treat cancer and immunological disorders
    Patent number: 11078291
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: August 3, 2021
    Assignee: Seagen Inc.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy
    Publication number: 20210206877
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders
    Type: Application
    Filed: December 7, 2020
    Publication date: July 8, 2021
    Applicants: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus
  • Rationally designed, synthetic antibody libraries and uses therefor
    Patent number: 11008568
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: May 18, 2021
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
    Patent number: 11008403
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 18, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar
  • Rationally designed, synthetic antibody libraries and uses therefor
    Patent number: 11008383
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: May 18, 2021
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • ANTIBODY LIBRARIES
    Publication number: 20210130813
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
    Type: Application
    Filed: November 2, 2020
    Publication date: May 6, 2021
    Inventors: Maximiliano Vasquez, Arvind Sivasubramanian, Michael Feldhaus
  • Antibody libraries
    Patent number: 10889811
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 12, 2021
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Arvind Sivasubramanian, Michael Feldhaus
  • Antibodies against BACE1 and use thereof for neural disease immunotherapy
    Patent number: 10882920
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: January 5, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus